{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:33:36Z","timestamp":1761352416106,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00280-021-04233-1","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T19:09:25Z","timestamp":1613675365000},"page":"579-583","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Severe toxicity of capecitabine in a patient with DPD deficiency after a safe FEC-100 experience: why we should test DPD deficiency in all patients before high-dose fluoropyrimidines"],"prefix":"10.1007","volume":"87","author":[{"given":"Maud","family":"Maillard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Eche-Gass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mony","family":"Ung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Brice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Marsili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florent","family":"Puisset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9886-412X","authenticated-orcid":false,"given":"Fabienne","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"key":"4233_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejca.2019.09.028","volume":"124","author":"C Barin-Le Guellec","year":"2020","unstructured":"Barin-Le Guellec C, Lafay-Chebassier C, Ingrand I et al (2020) Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: a real-life evaluation in France. Eur J Cancer Oxf Engl 1990 124:37\u201346. https:\/\/doi.org\/10.1016\/j.ejca.2019.09.028","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"4233_CR2","doi-asserted-by":"publisher","first-page":"e0175998","DOI":"10.1371\/journal.pone.0175998","volume":"12","author":"M-C Etienne-Grimaldi","year":"2017","unstructured":"Etienne-Grimaldi M-C, Boyer J-C, Beroud C et al (2017) New advances in DPYD genotype and risk of severe toxicity under capecitabine. PLoS ONE 12:e0175998. https:\/\/doi.org\/10.1371\/journal.pone.0175998","journal-title":"PLoS ONE"},{"key":"4233_CR3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1001\/jamaoncol.2015.5392","volume":"2","author":"V Boige","year":"2016","unstructured":"Boige V, Vincent M, Alexandre P et al (2016) DPYD genotyping to predict adverse events following treatment with fluorouracil-based adjuvant chemotherapy in patients with stage III colon cancer: a secondary analysis of the PETACC-8 randomized clinical trial. JAMA Oncol 2:655. https:\/\/doi.org\/10.1001\/jamaoncol.2015.5392","journal-title":"JAMA Oncol"},{"key":"4233_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1053\/j.seminoncol.2017.02.008","volume":"44","author":"M Boisdron-Celle","year":"2017","unstructured":"Boisdron-Celle M, Capitain O, Faroux R et al (2017) Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: assessment of a multiparametric approach. Semin Oncol 44:13\u201323. https:\/\/doi.org\/10.1053\/j.seminoncol.2017.02.008","journal-title":"Semin Oncol"},{"issue":"suppl_5","key":"4233_CR5","doi-asserted-by":"publisher","first-page":"v198","DOI":"10.1093\/annonc\/mdz246","volume":"30","author":"M Etienne-Grimaldi","year":"2019","unstructured":"Etienne-Grimaldi M, Cozic N, Boyer J et al (2019) FUSAFE Individual patient data meta-analysis (MA) to assess the performance of dihydropyrimidine dehydrogenase (DPD) gene polymorphisms for predicting grade 4\u20135 fluoropyrimidine (FP) toxicity. Annal Oncol 30(suppl_5):v198\u2013v252. https:\/\/doi.org\/10.1093\/annonc\/mdz246","journal-title":"Annal Oncol"},{"key":"4233_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz U, Henricks LM, Offer SM et al (2018) Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103:210\u2013216. https:\/\/doi.org\/10.1002\/cpt.911","journal-title":"Clin Pharmacol Ther"},{"key":"4233_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2018.02.001","author":"M-A Loriot","year":"2018","unstructured":"Loriot M-A, Ciccolini J, Thomas F et al (2018) Dihydropyrimidine dehydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: update and recommendations of the French GPCO-Unicancer and RNPGx networks. Bull Cancer (Paris). https:\/\/doi.org\/10.1016\/j.bulcan.2018.02.001","journal-title":"Bull Cancer (Paris)"},{"key":"4233_CR8","unstructured":"HAS-Sant\u00e9 (2018) Dihydropyrimidine dehydrogenase deficiency testing to prevent fluoropyrimidines-associated severe toxicities. https:\/\/www.has-sante.fr\/. Accessed 15 Oct 2020"},{"key":"4233_CR9","doi-asserted-by":"publisher","first-page":"bjc201794","DOI":"10.1038\/bjc.2017.94","volume":"116","author":"D Meulendijks","year":"2017","unstructured":"Meulendijks D, Henricks LM, Jacobs BAW et al (2017) Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer 116:bjc201794. https:\/\/doi.org\/10.1038\/bjc.2017.94","journal-title":"Br J Cancer"},{"key":"4233_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.canlet.2006.09.006","volume":"249","author":"M Boisdron-Celle","year":"2007","unstructured":"Boisdron-Celle M, Remaud G, Traore S et al (2007) 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 249:271\u2013282. https:\/\/doi.org\/10.1016\/j.canlet.2006.09.006","journal-title":"Cancer Lett"},{"key":"4233_CR11","first-page":"768","volume":"8","author":"MR Johnson","year":"2002","unstructured":"Johnson MR, Wang K, Diasio RB (2002) Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 8:768\u2013774","journal-title":"Clin Cancer Res"},{"key":"4233_CR12","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2217\/pgs-2019-0028","volume":"20","author":"CC Gbeto","year":"2019","unstructured":"Gbeto CC, Quaranta S, Mari R et al (2019) Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency. Pharmacogenomics 20:931\u2013938. https:\/\/doi.org\/10.2217\/pgs-2019-0028","journal-title":"Pharmacogenomics"},{"key":"4233_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/cpt.210","volume":"99","author":"F Thomas","year":"2016","unstructured":"Thomas F, Hennebelle I, Delmas C et al (2016) Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil\/uracil ratio. Clin Pharmacol Ther 99:235\u2013242. https:\/\/doi.org\/10.1002\/cpt.210","journal-title":"Clin Pharmacol Ther"},{"key":"4233_CR14","unstructured":"EMEA (2001) Xeloda, INN-capecitabine. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xeloda-epar-product-information_fr.pdf. Accessed 15 Oct 2020"},{"key":"4233_CR15","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1158\/0008-5472.CAN-13-2482","volume":"74","author":"SM Offer","year":"2014","unstructured":"Offer SM, Fossum CC, Wegner NJ et al (2014) Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res 74:2545\u20132554. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-2482","journal-title":"Cancer Res"},{"key":"4233_CR16","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","volume":"19","author":"LM Henricks","year":"2018","unstructured":"Henricks LM, Lunenburg CATC, de Man FM et al (2018) DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol 19:1459\u20131467. https:\/\/doi.org\/10.1016\/S1470-2045(18)30686-7","journal-title":"Lancet Oncol"},{"key":"4233_CR17","unstructured":"CPIC\u00ae (2020) Guideline for Fluoropyrimidines and DPYD. https:\/\/cpicpgx.org\/guidelines\/guideline-for-fluoropyrimidines-and-dpyd\/. Accessed 15 Oct 2020"},{"key":"4233_CR18","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1200\/JCO.1988.6.10.1653","volume":"6","author":"HM Pinedo","year":"1988","unstructured":"Pinedo HM, Peters GF (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6:1653\u20131664. https:\/\/doi.org\/10.1200\/JCO.1988.6.10.1653","journal-title":"J Clin Oncol"},{"key":"4233_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1067\/mcp.2000.109352","volume":"68","author":"C Terret","year":"2000","unstructured":"Terret C, Erdociain E, Guimbaud R et al (2000) Dose and time dependencies of 5-fluorouracil pharmacokinetics. Clin Pharmacol Ther 68:270\u2013279. https:\/\/doi.org\/10.1067\/mcp.2000.109352","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04233-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-021-04233-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04233-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T16:12:26Z","timestamp":1615392746000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-021-04233-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["4233"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04233-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"18 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The patient signed a consent form allowing the use of her biological results and samples for research purpose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The patient signed informed consent regarding publishing her data<i>.<\/i>","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}